| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Bilateral monopolies and location choice |
0 |
0 |
0 |
19 |
3 |
3 |
8 |
81 |
| Can Competition Reduce Quality? |
0 |
0 |
1 |
48 |
0 |
1 |
2 |
293 |
| Can competition reduce quality? |
0 |
0 |
0 |
38 |
1 |
4 |
5 |
85 |
| Can competition reduce quality? |
0 |
0 |
0 |
123 |
2 |
3 |
4 |
196 |
| Can competition reduce quality? |
1 |
1 |
2 |
110 |
1 |
6 |
10 |
313 |
| Capital Taxation and Imperfect Competition: ACE vs. CBIT |
0 |
0 |
0 |
17 |
3 |
5 |
6 |
103 |
| Capital Taxation and Imperfect Competition: ACE vs. CBIT |
0 |
0 |
0 |
8 |
2 |
6 |
7 |
52 |
| Capital Taxation and Imperfect Competition: ACE vs. CBIT |
0 |
0 |
0 |
16 |
1 |
2 |
4 |
67 |
| Capital Taxation and Imperfect Competition: ACE vs. CBIT |
0 |
0 |
0 |
12 |
0 |
1 |
2 |
57 |
| Capital taxation and imperfect competition: ACE vs. CBIT |
0 |
0 |
0 |
18 |
1 |
3 |
3 |
52 |
| Competing with precision: incentives for developing predictive biomarker tests |
0 |
0 |
0 |
27 |
2 |
7 |
7 |
17 |
| Competing with precision: incentives for developing predictive biomarker tests |
0 |
0 |
0 |
14 |
0 |
1 |
2 |
16 |
| Competition and Physician Behaviour: Does the Competitive Environment Affect the Propensity to Issue Sickness Certificates? |
0 |
0 |
0 |
11 |
1 |
4 |
5 |
46 |
| Competition and Quality in Regulated Markets with Sluggish Demand |
0 |
0 |
0 |
45 |
1 |
1 |
4 |
209 |
| Competition and Quality in Regulated Markets: a Differential-Game Approach |
0 |
0 |
0 |
82 |
2 |
2 |
3 |
386 |
| Competition and Waiting Times in Hospital Markets |
0 |
0 |
0 |
143 |
1 |
4 |
7 |
583 |
| Competition and Waiting Times in Hospital Markets |
0 |
0 |
0 |
108 |
0 |
4 |
8 |
416 |
| Competition and Waiting Times in Hospital Markets |
0 |
0 |
0 |
84 |
5 |
7 |
11 |
429 |
| Competition and physician behaviour: Does the competitive environment the propensity to issue sickness certificates? |
0 |
0 |
0 |
70 |
3 |
5 |
5 |
82 |
| Competition and quality in regulated markets with sluggish demand |
0 |
0 |
0 |
44 |
2 |
4 |
6 |
185 |
| Competition and quality in regulated markets: a differential-game approach |
0 |
0 |
1 |
150 |
3 |
4 |
8 |
495 |
| Competition and quality in regulated markets: a differential-game approach |
0 |
0 |
0 |
88 |
1 |
2 |
3 |
246 |
| Competition matters: uniform vs. indication-based pricing of pharmaceuticals |
0 |
1 |
16 |
16 |
2 |
5 |
37 |
37 |
| Competition matters: uniform vs. indication-based pricing of pharmaceuticals |
1 |
3 |
5 |
5 |
4 |
13 |
22 |
22 |
| Competition, quality and integrated health care |
0 |
0 |
0 |
67 |
1 |
2 |
3 |
78 |
| Diffusion of Pharmaceuticals: Cross-Country Evidence of Anti-TNF drugs |
0 |
0 |
0 |
28 |
1 |
4 |
4 |
100 |
| Direct to Consumer Advertising in Pharmaceutical Markets |
0 |
0 |
0 |
569 |
0 |
3 |
8 |
2,590 |
| Direct-to-Consumer Advertising in Pharmaceutical Markets |
0 |
0 |
0 |
16 |
2 |
2 |
3 |
101 |
| Direct-to-Consumer Advertising in Pharmaceutical Markets |
0 |
0 |
0 |
408 |
1 |
1 |
3 |
1,832 |
| Do Treatment Decisions Depend on Physicians` Financial Incentives? |
0 |
0 |
0 |
36 |
1 |
2 |
4 |
54 |
| Do Treatment Decisions Depend on Physicians’ Financial Incentives? |
0 |
0 |
0 |
10 |
0 |
2 |
5 |
70 |
| Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform |
0 |
0 |
0 |
18 |
0 |
0 |
1 |
86 |
| Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform |
0 |
1 |
1 |
23 |
1 |
6 |
7 |
20 |
| Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform |
0 |
0 |
0 |
72 |
1 |
2 |
3 |
154 |
| Gatekeeping In Health Care |
0 |
0 |
0 |
148 |
2 |
3 |
6 |
609 |
| Gatekeeping in Health Care |
0 |
0 |
0 |
252 |
9 |
11 |
16 |
1,825 |
| Gatekeeping in health care |
0 |
0 |
0 |
7 |
2 |
5 |
6 |
109 |
| Horizontal Mergers and Product Quality |
0 |
0 |
0 |
35 |
0 |
7 |
7 |
116 |
| Horizontal Mergers and Product Quality |
0 |
0 |
0 |
28 |
0 |
3 |
3 |
64 |
| Horizontal Mergers and Product Quality |
0 |
0 |
0 |
33 |
1 |
1 |
3 |
131 |
| Horizontal Mergers and Product Quality- |
0 |
0 |
0 |
60 |
2 |
3 |
3 |
144 |
| Hospital Competition and Quality with Regulated Prices |
0 |
0 |
0 |
306 |
3 |
4 |
5 |
1,113 |
| Hospital Competition in the National Health Service: Evidence from a Patient Choice Reform |
0 |
0 |
1 |
32 |
1 |
2 |
5 |
65 |
| Hospital Competition in the National Health Service: Evidence from a Patient Choice Reform |
0 |
0 |
0 |
70 |
0 |
3 |
5 |
144 |
| Hospital Competition with Soft Budgets |
0 |
0 |
0 |
48 |
6 |
9 |
10 |
202 |
| Hospital Mergers with Regulated Prices |
0 |
0 |
0 |
90 |
0 |
4 |
7 |
146 |
| Hospital Mergers: A Spatial Competition Approach |
0 |
0 |
0 |
121 |
0 |
1 |
2 |
117 |
| Hospital Mergers: A Spatial Competition Approach |
0 |
0 |
0 |
37 |
6 |
6 |
8 |
133 |
| Hospital Reimbursement in an Oligopolistic Industry |
0 |
0 |
0 |
0 |
1 |
1 |
2 |
1,043 |
| Hospital competition and quality with regulated prices |
0 |
0 |
0 |
149 |
1 |
2 |
5 |
389 |
| Hospital competition with soft budgets |
0 |
0 |
0 |
74 |
2 |
4 |
4 |
154 |
| Hospital competition with soft budgets |
0 |
0 |
0 |
46 |
0 |
0 |
0 |
123 |
| Hospital competition with soft budgets |
0 |
0 |
0 |
31 |
1 |
3 |
4 |
65 |
| How does the type of remuneration affect physician behaviour? Fixed salary versus fee-for-service |
1 |
1 |
3 |
73 |
2 |
4 |
8 |
148 |
| Margins and Market Shares: Pharmacy Incentives for Generic Substitution |
0 |
0 |
0 |
114 |
1 |
1 |
2 |
123 |
| Margins and Market Shares: Pharmacy Incentives for Generic Substitution |
0 |
0 |
0 |
36 |
5 |
10 |
14 |
217 |
| Margins and Market Shares:Pharmacy Incentives for Generic Substitution |
0 |
0 |
0 |
91 |
2 |
3 |
3 |
227 |
| Patents: Incentives for R&D or Marketing? |
0 |
0 |
0 |
9 |
0 |
3 |
5 |
54 |
| Patient Mobility, Health Care Quality and Welfare |
0 |
0 |
1 |
54 |
2 |
2 |
4 |
123 |
| Patient Mobility, Health Care Quality and Welfare |
0 |
0 |
0 |
42 |
0 |
2 |
4 |
124 |
| Patient Mobility, Health Care Quality and Welfare |
0 |
0 |
0 |
45 |
0 |
1 |
4 |
166 |
| Patient Mobility, Health Care Quality and Welfare |
0 |
0 |
0 |
51 |
2 |
5 |
5 |
157 |
| Patient mobility and health care quality when regions and patients differ in income |
0 |
0 |
1 |
14 |
3 |
3 |
5 |
71 |
| Paying for pharmaceuticals: uniform pricing versus two-part tariffs |
0 |
0 |
0 |
48 |
2 |
2 |
4 |
126 |
| Pharmaceutical Patents: Incentives for R&D or Marketing? |
0 |
0 |
0 |
275 |
1 |
4 |
7 |
1,095 |
| Price Regulation and Parallel Imports of Pharmaceuticals |
0 |
0 |
0 |
95 |
4 |
4 |
7 |
150 |
| Price Regulation and Parallel Imports of Pharmaceuticals |
0 |
0 |
0 |
100 |
1 |
2 |
3 |
121 |
| Price Regulation and Parallel Imports of Pharmaceuticals |
0 |
0 |
0 |
13 |
0 |
3 |
8 |
122 |
| Price and quality in spatial competition |
0 |
0 |
0 |
94 |
4 |
7 |
8 |
233 |
| Price and quality in spatial competition |
0 |
0 |
0 |
162 |
1 |
3 |
9 |
257 |
| Private Versus Public Health Care in a National Health Service |
0 |
1 |
2 |
1,283 |
4 |
5 |
14 |
6,006 |
| Public coverage of dental care: universal or targeted? |
0 |
0 |
0 |
0 |
4 |
7 |
14 |
14 |
| Public coverage of dental care: universal or targeted? |
0 |
1 |
9 |
9 |
5 |
7 |
16 |
16 |
| Public versus Private Health Care in a National Health Service |
0 |
0 |
0 |
1,228 |
1 |
2 |
3 |
6,642 |
| Quality and location choices under price regulation |
0 |
0 |
0 |
21 |
0 |
1 |
3 |
110 |
| Quality and location choices under price regulation |
0 |
1 |
1 |
26 |
2 |
4 |
6 |
111 |
| Quality competition with profit constraints: Do non-profit firms provide higher quality than for-profit firms? |
0 |
0 |
0 |
84 |
0 |
1 |
6 |
124 |
| Quality competition with profit constraints: Do non-profit firms provide higher quality than for-profit firms? |
0 |
0 |
0 |
44 |
0 |
0 |
1 |
146 |
| Quality competition with profit constraints: Do non-profit firms provide higher quality than for-profit firms? |
0 |
0 |
0 |
108 |
2 |
2 |
2 |
204 |
| Reference Pricing of Pharmaceuticals |
0 |
0 |
0 |
269 |
2 |
4 |
6 |
936 |
| Reference Pricing of Pharmaceuticals |
0 |
0 |
0 |
20 |
1 |
1 |
1 |
122 |
| Reference Pricing, Competition, and Pharmaceutical Expenditures: Theory and Evidence from a Natural Experiment |
1 |
1 |
9 |
112 |
3 |
5 |
18 |
403 |
| Reference pricing with endogenous generic entry |
0 |
0 |
0 |
52 |
1 |
2 |
2 |
92 |
| Reference pricing with endogenous generic entry |
0 |
0 |
0 |
16 |
1 |
2 |
3 |
78 |
| Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation? |
0 |
0 |
1 |
24 |
0 |
0 |
5 |
141 |
| Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation? |
0 |
0 |
0 |
308 |
1 |
4 |
4 |
1,348 |
| Regulation, generic competition and pharmaceutical prices: Theory and evidence from a natural experiment |
0 |
0 |
0 |
149 |
2 |
2 |
5 |
492 |
| Socioeconomic Status and PhysiciansíTreatment Decisions |
0 |
0 |
0 |
19 |
1 |
3 |
5 |
63 |
| Socioeconomic Status and Physicians’ Treatment Decisions |
0 |
0 |
0 |
10 |
5 |
8 |
10 |
80 |
| Taking the competitor´s pill: when combination therapies enter pharmaceutical markets |
0 |
0 |
0 |
0 |
2 |
3 |
3 |
7 |
| Taking the competitor’s pill: when combination therapies enter pharmaceutical markets |
0 |
0 |
0 |
12 |
0 |
2 |
6 |
27 |
| The price of cost-effectiveness thresholds |
0 |
0 |
1 |
27 |
0 |
3 |
5 |
20 |
| The price of cost-effectiveness thresholds |
0 |
0 |
0 |
24 |
0 |
3 |
8 |
19 |
| Trade, renewable energy, and market power in power markets |
2 |
2 |
2 |
17 |
5 |
10 |
17 |
49 |
| Where are all the Physicans? Private vs. Public Health Care |
0 |
0 |
0 |
1 |
2 |
2 |
3 |
3,326 |
| Total Working Papers |
6 |
13 |
57 |
9,289 |
160 |
335 |
587 |
40,335 |
| Journal Article |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Bilateral monopolies and location choice |
0 |
0 |
0 |
47 |
2 |
4 |
5 |
181 |
| Can Competition Reduce Quality? |
0 |
0 |
1 |
34 |
0 |
3 |
6 |
180 |
| Capital taxation and imperfect competition: ACE vs. CBIT |
0 |
0 |
0 |
15 |
1 |
3 |
8 |
103 |
| Competing with precision: incentives for developing predictive biomarker tests |
0 |
0 |
0 |
0 |
0 |
1 |
2 |
4 |
| Competition and physician behaviour: Does the competitive environment affect the propensity to issue sickness certificates? |
0 |
0 |
0 |
3 |
3 |
6 |
9 |
33 |
| Competition and quality in health care markets: A differential-game approach |
0 |
0 |
0 |
48 |
2 |
4 |
12 |
244 |
| Competition and waiting times in hospital markets |
0 |
0 |
1 |
133 |
4 |
7 |
11 |
513 |
| Competition in Regulated Markets with Sluggish Beliefs about Quality |
0 |
0 |
0 |
18 |
1 |
2 |
4 |
80 |
| Competition or Coordination in Hospital Markets with Unionised Labour |
0 |
0 |
0 |
31 |
3 |
3 |
5 |
190 |
| Competition policy for health care provision in Norway |
0 |
0 |
0 |
5 |
1 |
6 |
6 |
42 |
| Competition, quality and integrated health care |
0 |
0 |
0 |
4 |
3 |
5 |
9 |
19 |
| Diffusion of pharmaceuticals: cross-country evidence of anti-TNF drugs |
0 |
0 |
0 |
1 |
2 |
5 |
6 |
71 |
| Direct to consumer advertising in pharmaceutical markets |
0 |
0 |
0 |
114 |
0 |
3 |
3 |
339 |
| Do treatment decisions depend on physicians' financial incentives? |
0 |
0 |
4 |
43 |
1 |
3 |
18 |
169 |
| Gatekeeping in health care |
0 |
0 |
0 |
170 |
1 |
6 |
9 |
744 |
| Horizontal mergers and product quality |
0 |
0 |
0 |
8 |
1 |
2 |
6 |
59 |
| Horizontal mergers and product quality |
0 |
0 |
0 |
2 |
2 |
10 |
10 |
42 |
| Hospital Competition and Quality with Regulated Prices |
0 |
1 |
1 |
59 |
4 |
10 |
13 |
207 |
| Hospital Competition with Soft Budgets |
0 |
0 |
0 |
9 |
2 |
3 |
4 |
67 |
| Hospital Mergers with Regulated Prices |
0 |
0 |
0 |
5 |
4 |
6 |
7 |
64 |
| Hospital competition in a national health service: Evidence from a patient choice reform |
0 |
0 |
1 |
6 |
1 |
3 |
8 |
35 |
| How Does The Type of Remuneration Affect Physician Behavior? |
0 |
0 |
1 |
31 |
2 |
5 |
17 |
98 |
| Margins and market shares: Pharmacy incentives for generic substitution |
0 |
1 |
1 |
56 |
0 |
4 |
12 |
331 |
| Patient mobility and health care quality when regions and patients differ in income |
0 |
0 |
1 |
18 |
0 |
1 |
4 |
79 |
| Patient mobility, health care quality and welfare |
0 |
0 |
1 |
22 |
1 |
3 |
6 |
104 |
| Paying for pharmaceuticals: uniform pricing versus two-part tariffs |
0 |
1 |
1 |
4 |
2 |
4 |
5 |
24 |
| Pharmaceutical Patents: Incentives for Research and Development or Marketing? |
0 |
0 |
0 |
0 |
0 |
1 |
4 |
6 |
| Price and quality in spatial competition |
0 |
0 |
0 |
57 |
0 |
3 |
9 |
249 |
| Price regulation and parallel imports of pharmaceuticals |
0 |
0 |
0 |
24 |
3 |
6 |
8 |
119 |
| Public versus private health care in a national health service |
0 |
0 |
0 |
168 |
2 |
3 |
3 |
690 |
| Quality and Location Choices under Price Regulation |
0 |
1 |
2 |
171 |
1 |
5 |
8 |
503 |
| Quality competition with profit constraints |
0 |
0 |
1 |
33 |
1 |
2 |
10 |
170 |
| Reference pricing of pharmaceuticals |
0 |
0 |
0 |
97 |
1 |
4 |
5 |
262 |
| Reference pricing with endogenous generic entry |
0 |
1 |
1 |
13 |
2 |
8 |
11 |
67 |
| Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment |
0 |
0 |
0 |
75 |
1 |
7 |
14 |
348 |
| Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment |
0 |
1 |
2 |
75 |
0 |
1 |
4 |
252 |
| Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation? |
0 |
0 |
2 |
132 |
2 |
6 |
10 |
417 |
| Socio‐economic status and physicians' treatment decisions |
0 |
0 |
1 |
7 |
2 |
3 |
4 |
36 |
| Taking the competitor’s pill: When combination therapies enter pharmaceutical markets |
0 |
0 |
0 |
0 |
4 |
7 |
8 |
8 |
| The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets |
0 |
0 |
0 |
4 |
1 |
3 |
9 |
24 |
| Trade, renewable energy, and market power in power markets |
1 |
4 |
4 |
4 |
7 |
15 |
15 |
15 |
| Total Journal Articles |
1 |
10 |
26 |
1,746 |
70 |
186 |
327 |
7,188 |
LogEc is hosted by the
Örebro University School of Business.